METHODS FOR PREDICTING PROSTATE CANCER RECURRENCE

• US 20090017463A1
• Filed: 07/10/2008
• Published: 01/15/2009
• Est. Priority Date: 07/10/2007
• Status: Abandoned Application

• Current Assignee: Vanderbilt University
• Original Assignee: Vanderbilt University
• Inventors: BHOWMICK, NEIL A.
• Application Number:
  US12/170,913
• Publication Number:
  US 20090017463A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: G01N 2800/56 Staging of a disease; Further complications associated with the disease
• CPC Class Codes: G01N 2800/60 Complex ways of combining multiple protein biomarkers for diagnosis
• CPC Class Codes: G01N 33/57434 of prostate

Abstract

The present invention relates to the identification of four cytokine biomarkers in prostatic tissue that exhibit differential expression following prostatectomy that, in combination at least one other factor, are able to reliably predict the development of biochemical recurrence following surgery. This marker combination improves the risk stratification of patients after primary local treatment for localized prostate cancer.

Claims

1. A method of predicting the post-surgical progression of prostate cancer in a subject comprising:

(a) assessing the level of MIP1β

, fractalkine and IL-15 in a tumor sample;

(b) assessing at least one additional prognostic factor; and

(c) predicting the post-surgical progression of prostate cancer in said subject.

2. The method of claim 1, wherein said at least one additional factor is pre-surgical PSA, IL-1α

expression level, stage, prostate capsule invasion, surgical margin status, seminal vesicle involvement, lymph node involvement, IP-10 level and/or Gleason grade.

3. The method of claim 1, wherein said at least one additional factor is pre-surgical PSA

4. The method of claim 1, wherein said at least one additional factor is Gleason grade

5. The method of claim 1, wherein said at least one additional factor is IP-10 level.

6. The method of claim 1, wherein step (a) comprises real-time PCR.

7. The method of claim 1, wherein step (a) comprises immunohistochemistry.

8. The method of claim 1, wherein step (a) comprises ELISA.

9. The method of claim 8, wherein said tumor sample is subjected to lectin-based protein enrichment.

10. The method of claim 1, further comprising making a post-operative treatment or monitoring decision.

11. The method of claim 10, wherein said treatment decision is to administer anti-androgens or chemotherapeutics.

12. The method of 10, wherein said monitoring decision is to perform frequent disease surveillance.